Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals is a biopharmaceutical company developing and commercializing therapies for rare and orphan diseases, primarily those affecting the liver and bile acid metabolism. The company's marketed products include LIVMARLI (maralixibat), an oral ileal bile acid transporter inhibitor approved for treating cholestatic pruritus in patients with Alagille syndrome in the United States and select international markets. LIVMARLI represents the company's lead commercial product and primary revenue driver. Mirum also commercializes two additional approved therapies: Cholbam (cholic acid capsule) for bile acid synthesis disorders and certain peroxisomal disorders, and Chenodal (chenodeoxycholic acid tablet) for radiolucent gallstones.

The company maintains a pipeline of development-stage candidates, including Volixibat, an oral IBAT inhibitor in Phase 2b testing for cholestatic liver diseases in adult patients, and Chenodal in Phase 3 development for cerebrotendinous xanthomatosis. These programs target patient populations with limited therapeutic options and significant unmet medical needs.

Mirum Pharmaceuticals was incorporated in Delaware in 2018 and is headquartered in Foster City, California. The company operates primarily within the United States and select international markets where its approved products are marketed and distributed.